Clinical TrialsSearch results for "cytarabine"
Number of results: 75
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29
Completed
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Acute Myeloid Leukemia
- Omote Masayuki
- 2022-11-29